J Korean Endocr Soc.  2007 Oct;22(5):323-325. 10.3803/jkes.2007.22.5.323.

Clinical Manifestation of Polycysticv Ovary Syndrome

• Ahn YB

• KMID: 1523100
• DOI: http://doi.org/10.3803/jkes.2007.22.5.323

Abstract

No abstract available.

MeSH Terms

Female
Ovary*

Reference

1. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005. 352:1223–1236.

2. Hahn S, Tan S, Elsenbruch S, Quadbeck B, Herrmann BL, Mann K, Janssen OE. Clinical and biochemical characterization of women with polycystic ovary syndrome in North Rhine-Westphalia. Horm Metab Res. 2005. 37:438–444.

3. Kumar A, Woods KS, Bartolucci AA, Azziz R. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin Endocrinol. 2005. 62:44–49.

4. Wood JR, Ho CK, Nelson-Degrave VL, McAllister JM, Strauss JF 3rd. The molecular signature of polycystic ovary syndrome (PCOS) theca cells defi ned by gene expression profi ling. J Reprod Immunol. 2004. 63:51–60.

5. Willis D, Mason H, Gilling-Smith C, Franks S. Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. J Clin Endocrinol Metab. 1996. 81:302–309.

6. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004. 19:41–47.

7. Goodarzi MO, Quinones MJ, Azziz R, Rotter JI, Hsueh WA, Yang H. Polycystic ovary syndrome in Mexican-Americans: prevalence and association with the severity of insulin resistance. Fertil Steril. 2005. 84:766 –769.

8. Carmina E, Chu MC, Longo RA, Rini GB, Lobo RA. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab. 2005. 90:2545–2549.

9. Carmina E, Rosato F, Janni A, Rizzo M, Longo RA. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab. 2006. 91:2–6.

11. Dewailly D, Catteau-Jonard S, Reyss AC, Leroy M, Pigny P. Oligo-anovulation with polycystic ovaries (PCO) but not overt hyperandrogenism. J Clin Endocrinol Metab. 2006. 91:3922–3927.

12. Pehlivanov B, Orbetzova M. Characteristics of different phenotypes of polycystic ovary syndrome in a Bulgarian population. Gynecol Endocrinol. 2007. 23:604–609.

13. Diamanti-Kandarakis E, Kouli C, Tsianateil T, Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol. 1998. 138:269–274.

14. Franks S, McCarthy MI, Hardy K. Development of polycystic ovary syndrome: involvement of genetic and environmental factors. Int J Androl. 2006. 29:278–285.

15. Pyun GW, Choi YJ, Lee HJ, Oh JY, Hong YS, Sung YA, Chung HW. Phenotypic variation of polycystic ovary syndrome. J Kor Endocrine Soc. 2007. 22:326–331.